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A series of 45 peptide inhibitors was designed, synthesized, and evaluated against the NS2B–NS3 prote-
ases of the four subtypes of dengue virus, DEN-1–4. The design was based on proteochemometric models
for Michaelis (Km) and cleavage rate constants (kcat) of protease substrates. This led ﬁrst to octapeptides
showing submicromolar or low micromolar inhibitory activities on the four proteases. Stepwise removal
of cationic substrate non-prime side residues and variations in the prime side sequence resulted ﬁnally in
an uncharged tetrapeptide, WYCW-NH2, with inhibitory Ki values of 4.2, 4.8, 24.4, and 11.2 lM for the
DEN-1–4 proteases, respectively. Analysis of the inhibition data by proteochemometric modeling sug-
gested the possibility for different binding poses of the shortened peptides compared to the octapeptides,
which was supported by results of docking of WYCW-NH2 into the X-ray structure of DEN-3 protease.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Mosquito-borne dengue virus belongs to the genus Flavivirus
that comprises over 70 viruses many of which are human patho-
gens such as West Nile virus, yellow fever virus, and Japanese
encephalitis virus. Infection by dengue virus causes symptoms
from mild fever to life-threatening dengue hemorrhagic fever
and dengue shock syndrome. The virus is endemic to most tropical
and subtropical regions, with more than 2.5 billion people at risk
for epidemic transmission, and an estimated 50 million infections
each year. There are four highly homologous but antigenically dis-
tinct serotypes of the virus (DEN-1–4), and immunity against one
serotype does not protect against infection by another serotype;
instead it may enhance disease severity upon infection with an-
other serotype [1].
Currently there are no antiviral drugs available against ﬂavivi-
ruses. An attractive target for development of therapeutic inhibi-
tors is the two-component viral protease NS2B–NS3. The
ﬂaviviral NS3 protein is a multifunctional enzyme that possesses
protease, helicase and RNA triphosphatase activities. The N-termi-r Inc.
4; PCM, proteochemometric;
zoic acid; nY, 3-nitrotyrosine.
Wikberg).
Open access under CC BY licensenal domain of about 180 amino acids of NS3 is a trypsin-like serine
protease, which adopt a chemotrypsin-like fold with two b-barrels,
each formed by six b-strands, with the catalytic triad His51-Asp75-
Ser135 located at the cleft between the b-barrels. For full
enzymatic activity the protease requires the hydrophilic part of
the integral membrane protein NS2B (residues 49–95). Several X-
ray crystal structures of dengue andWest Nile virus proteases have
been determined. In all of them the NS2B cofactor is located at a
distance from the substrate binding site in ligand-free protease
and is lining the substrate binding site in the inhibitor-bound
protease. In the latter conformation, NS2B provides a b-strand to
the N-terminal b-barrel and stabilizes this domain by covering
hydrophobic residues of NS3 [2–4].
Considerable efforts have been recently made to ﬁnd inhibitors
to proteases of dengue virus, West Nile virus, and other ﬂavivi-
ruses. Peptide inhibitors for dengue NS2B–NS3 showing lowmicro-
molar activities were recently reported [5,6]. Such inhibitors were
based on non-prime side sequences of substrate cleavage sites; all
which contain basic amino acids at the P1 and P2 positions and
often also at the P3 and P4 positions [7]. High charge is associated
with poor membrane permeability, however, making non-prime
side sequences unattractive as antivirals. This is because viral
replication occurs intracellularly, and without cell-penetration
the compound will be ineffective.
Small molecule inhibitors of dengue NS2B–NS3 reaching low
micromolar activities were also reported, which included anthra-
cene [8] and phthalazine-based compounds [9], and ﬂavonoids.
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aromatic scaffolds were also found, which inhibited NS2B–NS3
proteases of West Nile and yellow fever viruses [11–14].
In a previous study we investigated the prime side speciﬁcity of
dengue virus NS2B–NS3 protease substrates [15]. Using statistical
experimental design we selected a set of 48 internally quenched
peptides with the general structure Abz-RRRR|XXXX-nY-NH2
(where Abz is o-aminobenzoic acid and nY is 3-nitrotyrosine).
Thus, the non-prime side sequence of all these peptides corre-
sponded to the sequence of the cleavage site of DEN-2 capsid
protein, while for the P01–P04 positions 6–10 amino acids were var-
ied for each position under the constraint of D-optimal design [16].
The peptides were synthesized and assayed with DEN-1–4 NS2B–
NS3 proteases for Michaelis (Km) and cleavage rate constants (kcat).
The results were analyzed by proteochemometric (PCM) modeling,
which showed that different physico-chemical properties of amino
acids contributed independently to the two activities. It was e.g.
found that the presence of hydrophobic or rigid amino acids at
the P01 position is disadvantageous for substrate cleavage, while
on the other hand they exert less inﬂuence on substrate binding.
Interpretation of the PCM model also suggested that a cysteine in
the P03 position gives better binding (i.e. lower Km) than any of
the amino acids present at P03 in dengue virus’ native cleavage
sites. Moreover, most of the peptides with C in the P03 or P04 posi-
tions showed substrate inhibition, and furthermore a peptide with
the prime side sequence GWCF was non-cleavable by all the DEN-
1–4 proteases. These ﬁndings indicated the possibility for design of
new peptides acting as inhibitors of dengue proteases. In this study
we exploited this ﬁnding, which resulted in an uncharged peptide
with micromolar inhibitory activity on the NS2B–NS3 proteases
from four different dengue serotypes.2. Materials and methods
2.1. Expression and puriﬁcation of dengue virus proteases
We used our previously described pTrcHis plasmids contain-
ing dengue virus protease sequences [17]. Expression of
NS2B(H)–NS3pro from these plasmids was done in Escherichia
coli. Dengue virus type 2–4 proteases were puriﬁed from inclu-
sion bodies and refolded, as described previously [17]. Dengue
virus type 1 protease was puriﬁed from supernatants, as
described previously [18].
2.2. Synthesis of peptides
Forty-ﬁve peptides were prepared by solid-phase synthesis
using an automated multiple peptide synthesizer (MultiPep;
Intavis Bioanalytical Instruments AG, Koeln, Germany), using its
automated standard protocol optimized for Fmoc chemistry as
described previously [15]. All chemicals were reagent grade from
Fluka (Sigma–Aldrich, St. Louis, MO, USA), Applied Biosystems
(Foster City, CA, USA), Bachem (Bubendorf, Switzerland) and Nova-
biochem (Calbiochem-Novabiochem AG, Laufelﬁngen, Switzer-
land). Peptides were characterized by HPLC and their structures
were conﬁrmed by MS as described [15]. The purity of raw pep-
tides was above 80%. After small-scale preparative HPLC the purity
of all peptides was above 95% and they were used for inhibitor
assays after freeze drying as described [15].
2.3. Inhibitor assay
The ﬂuorogenic assay was carried out with the ﬂuorogenic sub-
strate Abz-RRRRSAG-nY-NH2 on a FLUOstar OPTIMA 96-well plate
reader (BMG Labtech GmbH), monitoring emission at 420 nm uponexcitation at 320 nm. The ﬁnal reaction volume was 100 lL and
contained 50 mM Tris–HCl, pH 9.0 and 20% glycerol. Typically, test
compounds were pre-incubated with 150 nM protease at 37 C for
20 min. Substrate cleavage was then initiated by the addition of
substrate at 10 lM ﬁnal concentration. Reaction progress was
monitored continuously during 60 min. Each test compound was
diluted 1:2 from a 100 lM stock solution, with totally 11 dilution
points for each test compound. For compounds that showed low
activity the assay was repeated starting from 500 lM concentra-
tion. For controls only solvent was used. Inhibition constant Ki val-
ues were determined from dose–response curves using GraFit
version 5 software.
2.4. Proteochemometric modeling of activity data
The inhibition Ki data for the 45 peptides for the four proteases
was concomitantly analyzed by proteochemometric modeling
(PCM), which aims at ﬁnding a quantitative relationship between
the interaction data and descriptors of the interacting moieties
[19].
For the PCM, the peptides were characterized by 14 descriptors.
Five of these were binary and represented: (1) presence or absence
of Abz and nY groups, (2) acetylation or non-acetylation of N-ter-
minus, and (3–5) presence of at least one arginine, two arginines,
or four arginines in the peptide. The remainder of the descriptors
were obtained by characterizing each prime side residue with
three quantitative physico-chemical z-scale descriptors [20], which
gave totally nine descriptors for the varied P01, P02, and P04 resi-
dues. (The invariant cysteine residue was viewed as to be located
at the P03 position for all peptides.) The three z-scales can be inter-
preted as representing hydrophilicity, steric properties, and polar-
ity of amino acids. The four proteases were represented by four
binary descriptors, where each protease was assigned the value 1
for one of the descriptors and 0 for the three others. All descriptors
were mean centered and scaled to unit variance. The response var-
iable (pKi, i.e. negative logarithm of Ki value for DEN-1–4 protease
inhibition) was also mean centered. For the case that a peptide did
not show inhibitory activity, we assigned it pKi = 3 for the sake of
the PCM modeling (i.e. one millimolar activity).
The relationships between the descriptors and the response
were established by partial least squares regression (PLS) using
the OPLS algorithm as implemented in Simca-P+11 software
(Umetrics AB). The optimal complexity of the PLS model was esti-
mated by ﬁvefold cross-validation, leaving out data for 1/5 of the
peptides at a time. Thus, all data for any peptide (i.e. inhibition
of DEN-1–4 proteases) were assigned to the same cross-validation
group to avoid risk for model overﬁt for the case that a peptide
shows similar activities against DEN-1–4. Overestimations of pre-
dictive performance and overﬁts may also occur if compounds
used in model evaluation are very similar to the compounds in
the model. To eliminate such risk, pairs of peptides that differed
only by acetylation of the N-terminus were also included in the
same cross validation group (e.g. WYCW-NH2 was placed in the
same group as Ac-WYCW-NH2, etc.).
2.5. Molecular docking
The most active tetrapeptide found herein, WYCW-NH2, was
docked into the dengue virus protease using the recently solved
crystal structure of DEN-3 NS2B–NS3 protease in complex with
the aldehyde inhibitor Bz-nKRR-H (PDB code 3U1I) [4]. Prior to
the docking the embedded inhibitor, water molecules and ions
were removed from the PDB ﬁle, and polar hydrogen atoms were
added using AutoDock Tools software [21]. The docking was per-
formed by AutoDock Vina software [22]. The search space covered
the whole NS2B–NS3 complex.
P. Prusis et al. / Biochemical and Biophysical Research Communications 434 (2013) 767–772 7693. Results and discussion
3.1. Peptide library
In the ﬁrst part of this study we designed and synthesized a set
of substrate-like octapeptides with four arginines at the P4–P1
positions, and tested their inhibitory activity (Ki) on DEN-1–4 pro-
teases. Subsequently, we studied changes on inhibitory activities
caused by shortenings and other modiﬁcations of the peptides.
Finally, we performed PCM analysis and 3D docking of the most ac-
tive short peptide found into the DEN-3 NS2–NS3 protease
complex.
The sequences and inhibitory activities of all the 45 peptides
designed and evaluated herein are presented in Table 1. Peptides
Sp131–Sp139 were directed for experimental validation of our ear-
lier proteochemometric model for Michaelis (Km) and cleavage rate
constants (kcat) of dengue protease substrates [15]. Sp131–Sp139
were of the same type as in our previous study, Abz-RRRRXXXX-
nY-NH2 [15], and were designed to gain low Km and/or low kcat
values; i.e. to bind tight with low rate of cleavage. These were
designed by ﬁrst selecting amino acids at each position that wereTable 1
Inhibition of dengue virus NS2B–NS3 protease by peptide inhibitors (Ki values are in lM)
Name Sequence Ki (DEN-1)
Sp131 Abz-RRRRYWCG-nY-NH2 1.3
Sp132 Abz-RRRRGWCG-nY-NH2 No inhib.b
Sp133 Abz-RRRRWYCG-nY-NH2 0.7
Sp134 Abz-RRRRMVCG-nY-NH2 1.7
Sp135 Abz-RRRRMGCG-nY-NH2 No inhib.
Sp136 Abz-RRRRWWCG-nY-NH2 1.3
Sp137 Abz-RRRRMYCC-nY-NH2 2.5
Sp138 Abz-RRRRYVCC-nY-NH2 2.3
Sp139 Abz-RRRRGGCC-nY-NH2 No inhib.
SRP-01 Abz-RRRRHWCC-nY-NH2 1.3
SRP-02 Abz-RRRRHWCA-nY-NH2 0.6
SRP-03 Abz-RRRRHWCW-nY-NH2 0.6
SRP-04 Abz-RRRRHLCC-nY-NH2 2.8
SRP-05 Abz-RRRRHLCA-nY-NH2 0.6
SRP-06 Abz-RRRRHLCW-nY-NH2 0.3
SRP-07 Abz-RRRRWW-nY-NH2 2.7
SRP-08 Abz-RRRRWY-nY-NH2 10.3
SRP-09 Abz-RRWWCC-nY-NH2 1.7
SRP-10 Abz-RRWYCG-nY-NH2 3.3
SRP-11 Abz-WWCC-nY-NH2 No inhib.
SRP-12 Abz-WYCG-nY-NH2 10.2
SRP-13 RRRRHWCW-NH2 0.4
SRP-14 RRHWCW-NH2 5.4
SRP-15 RHWCW-NH2 13.1
SRP-16 HWCW-NH2 No inhib.
SRP-17 RRRRHLCW-NH2 0.3
SRP-18 RRHLCW-NH2 5.7
SRP-19 RHLCW-NH2 No inhib.
SRP-20 HLCW-NH2 No inhib.
SRP-21 RWYCG-NH2 No inhib.
SRP-22 WYCG-NH2 No inhib.
SRP-23 RWWCC-NH2 19.5
SRP-24 WYCW-NH2 4.2
SRP-25 Ac-RRRRHWCW-NH2 0.4
SRP-26 Ac-RRHWCW-NH2 5.0
SRP-27 Ac-RHWCW-NH2 16.6
SRP-28 Ac-HWCW-NH2 No inhib.
SRP-29 Ac-RRRRHLCW-NH2 0.6
SRP-30 Ac-RRHLCW-NH2 10.1
SRP-31 Ac-RHLCW-NH2 No inhib.
SRP-32 Ac-HLCW-NH2 No inhib.
SRP-33 Ac-RWYCG-NH2 No inhib.
SRP-34 Ac-WYCG-NH2 No inhib.
SRP-35 Ac-RWWCC-NH2 45.1
SRP-36 Ac-WYCW-NH2 9.0
a Not tested.
b No activity at 100 lM.predicted to be favorable by the proteochemometric model.
Selected amino acids were W, Y, G, or M for the P01 position; W,
Y, G, or V for the P02 position; C for the P03 position; and C or G
for the P04 position. This thus gave 4  4  1  2 = 32 possible pep-
tide sequences. Applying D-optimal design on this set gave a
diverse and representative subset, comprising Sp131–Sp139.
Experimental testing showed that six of the nine peptides exhib-
ited high inhibitory activity. Only peptides with G at the P01 and/
or P02 positions were inactive.
Peptides SRP-1–SRP-36 were then designed aiming to achieve
higher inhibitory activity, and to study the effects of truncation
at the cationic non-prime side. As seen from Table 1, peptides
SRP-1–SRP-6, which have the general structure Abz-RRRRHXCX-
nY-NH2, show Ki values in the range of 1–10 lM on all four prote-
ases. Peptides SRP-13 and SRP-17, which are analogs of SRP-3 and
SRP-5, which lack the Abz and nY groups, show even higher inhib-
itory activities. This thus indicates that the ﬂuorogenic groups orig-
inally used for assaying substrate cleavage do not contribute to the
protease inhibition.
Truncations at the P side generally led to decreased activity (cf.
results for SRP-13, SRP-14, SRP-15, and SRP-16). Of the four.
Ki (DEN-2) Ki (DEN-3) Ki (DEN-4)
2.1 3.0 –a
No inhib. No inhib. –
2.0 1.9 –
3.2 2.1 –
No inhib. No inhib. –
2.2 2.2 2.9
5.5 4.0 4.1
4.8 4.0 3.1
No inhib. No inhib. No inhib.
3.7 1.6 3.0
1.9 0.9 2.5
1.1 0.7 3.3
8.3 5.4 2.9
3.6 1.4 2.9
1.1 0.5 1.9
44.3 5.3 3.1
26.8 9.8 4.7
2.7 2.3 4.7
4.7 2.8 9.8
No inhib. No inhib. No inhib.
13.5 20% at 100 lM 20.1
0.3 0.5 2.2
8.7 5.2 8.5
142.6 25.7 24.9
No inhib. No inhib. No inhib.
0.4 0.7 2.2
9.9 7.5 9.1
No inhib. No inhib. No inhib.
No inhib. No inhib. No inhib.
No inhib. No inhib. No inhib.
No inhib. No inhib. No inhib.
39.0 15.4 9.5
4.8 24.4 11.2
0.3 0.6 2.7
8.2 5.2 6.2
6.3 25.8 17.9
No inhib. No inhib. No inhib.
1.1 0.6 2.6
5.1 17.0 11.5
No inhib. No inhib. No inhib.
No inhib. No inhib. No inhib.
No inhib. No inhib. No inhib.
No inhib. No inhib. No inhib.
9.5 37.6 42.8
18.0 75.1 55.9
Fig. 1. Correlation of calculated versus measured inhibition activities. Shown are
calculated versus measured pKi values for inhibition of DEN-1–4 virus S2B–NS3
protease by the 45 peptides studied herein, according to the PCM model developed
without use of cross-terms (for details see text).
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found to be inactive. However, one with the sequence WYCW-
NH2 (SRP-24) showed inhibitory Ki values ranging from 4.8 to
24.4 lM on the four dengue proteases.
Another interesting observation was that, while tetrapeptide
SRP-22 (WYCG-NH2) was inactive, peptide SRP-12 (Abz-WYCG-
nY-NH2) showed high inhibitory activity against three of the four
proteases. We may speculate that this is due to that no steric hin-
drance takes place from the neighboring G residue so that nY can
adopt a conformation that is favorable for interactions with the
protease.
Peptides SRP-25–SRP-36 were directed to investigate the inﬂu-
ence of acetylation of the N-terminus. These peptides were synthe-
sized in parallel with the non-acetylated analogs (SRP-13–SRP-24).
In most cases the acetylated peptides showed similar or up to two-
fold lower activity than the non-acetylated ones. Nevertheless, in
one case (SRP-27) the activity was higher than for its non-acety-
lated variant (SRP-15) (6.3 lM versus 142.6 lM against the DEN-
2 protease).
We equipped the ﬁrst 24 peptides of the series (Sp131–Sp139
and SRP-1–SRP-12) with internally quenched ﬂuorogenic groups
to get an indication if a peptide was cleaved by the protease and
thus acted as a competitive substrate rather than inhibitor. But
no increase of background ﬂuorescence during the pre-incubation
with the protease was evident for any of these peptides. Peptides
SRP-13–SRP-36 were not labeled by ﬂuorogenic groups because
they either were shortened or acetylated analogs of SRP-1–SRP-
12 or did not contain the cationic substrate cleavage site residues.3.2. Analysis of the interaction data by proteochemometric modeling
In order to estimate quantitatively the inﬂuence of peptide
properties for inhibitory activity we performed PCM modeling. To
this end, the peptides were characterized by ﬁve binary and nine
quantitative physico-chemical descriptors while the proteases
were described by four binary descriptors (see Section 2.4 for de-
tails). The relationship between the descriptors of the 45 peptides
and four proteases to the logarithmically transformed inhibitory
activity data (pKi) was established by partial least squares regres-
sion, which created a single uniﬁed PCM model. The PCM model
comprised ﬁve PLS components, explaining R2 = 0.83 of the varia-
tion of the pKi data, and having the predictive ability according
to ﬁvefold cross-validation Q2 = 0.69.
The correlation of calculated versus measured pKi values by the
PCM model is presented graphically in Fig. 1. As indicated by the
ovals in the ﬁgure, the activities of three short peptides, namely
SRP-12, SRP-24, and SRP-27, were underestimated by about one
logarithmic unit, while the activities for one peptide, SRP-36, were
overestimated for the four proteases. For most of the peptides cal-
culation errors were below 0.3 logarithmic units, which in fact is
comparable to the measurement errors of the inhibition assays.
PLS derives a regression equation where the regression coefﬁ-
cients indicate the inﬂuence of the described properties on the re-
sponse [23]. Since the response in the PCMmodel was the negative
logarithm of the measured Ki values, a positive coefﬁcient indicates
that the represented property increases the inhibitory activity,
while a negative coefﬁcient indicates the opposite.
As seen in Fig. 2, high positive coefﬁcients are given to the R2
and R4 descriptors, which characterize the presence of at least
two (R2) or four (R4) arginine residues in the peptides. A positive
coefﬁcient is also given to the Abz-nY descriptor, which represents
the presence of ﬂuorogenic groups. When one interprets the coef-
ﬁcient for this descriptor one should take into account that ﬂuoro-
genic groups are predominantly present in the longest peptides,
and hence that the descriptor correlates with the R2 and R4descriptors. Nevertheless, the Abz-nY descriptor explains partially
the high activity of the SRP-12 peptide.
Analyzing the z-scale descriptors gives further information. As
the z2-scale represents steric properties of amino acids, the large
positive coefﬁcient for 1z2 indicates that placing a small amino
acid at P01 should result in peptides with essentially no inhibitory
activity. (A plausible explanation for this is that the small G and S,
which are the most common amino acids at P01 among substrates
of dengue proteases, facilitate substrate cleavage, as is indicated by
our previous PCMmodeling of kcat data.) The z1-scale characterizes
hydrophilicity of amino acids. Hence, the negative coefﬁcients for
the 1z1 and 4z1 descriptors indicate a need for hydrophobic amino
acids in the peptide, to achieve inhibitory activity.
The regression coefﬁcients for z-scale descriptors at the P02 po-
sition are relatively small and within their conﬁdence intervals,
which means that one should not draw too strong conclusions
about the preferable amino acid(s) at this position. In fact, this
may mean that different amino acids are preferred at this position
in different peptides. Detailed inspection of the activity data in
Table 1 suggests that a broader variation of amino acids is accept-
able in the longest peptides (e.g. aliphatic V and L are tolerated, as
well as aromatic W and Y), whereas in the shortest peptides the
requirements are more strict (e.g. rendering HWCW-NH2 and
HLCW-NH2 inactive). To test this hypothesis, we created a new
PCM model, which included nine cross-terms obtained by multi-
plying descriptors 2z1, 2z2, and 2z3 with R1, R2, and R4. The model
where 18 original descriptors were complemented with 9 cross-
terms showed superior performance; the goodness of ﬁt being
R2 = 0.92 and the predictive ability Q2 = 0.79 (compared these val-
ues with the R2 = 0.83 and Q2 = 0.69 of the initial model), and the
model could better explain the high activities of SRP-12, SRP-24,
and SRP-27.
In an attempt to further improve the predictive ability of the
PCMmodel we complemented the 14 descriptors with cross-terms
between peptide and protease descriptors. In PCM, use of such
cross-terms allows explaining the differences in ligand–protein
selectivity. However, few of the cross-terms obtained signiﬁcant
regression coefﬁcients (i.e. they did not fall outside their
Fig. 2. Inﬂuence of peptide and protease properties on the inhibitory activity. Shown are regression coefﬁcients from the PLS regression equation correlating peptide and
protease descriptors to their inhibitory activity (pKi) against proteases of DEN-1–4 virus (i.e. the PCM model without cross-terms). A positive coefﬁcient indicates a positive
correlation for the described peptide property and the inhibitory activity, whereas a negative coefﬁcient indicates a negative correlation. Shown are also conﬁdence intervals
of regression coefﬁcients calculated from ﬁvefold cross-validation at a conﬁdence level of 95%.
Fig. 3. Results of docking of peptide SRP-24 (WYCW-NH2) into X-ray structure of NS2B–NS3 protease of DEN-3 virus. (A) Surface view of dengue 3 virus NS2B–NS3 protease
(PDB code 3U1I) with docked tetrapeptide WYCW-NH2. Shown are superimpositions of the lowest energy docking poses of ﬁve docking runs. The NS2B unit is shown in cyan,
and the NS3 unit in green. The catalytic triad (H51, D75, and S135) is colored red. (B) Close-up of the surface view of the active site with the docked peptide. (C) Close-up of a
ribbon view of the active site with docked peptide. Red sticks represent catalytic triad residues H51, D75, and S135, and S1 pocket residue Y161. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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improved predictive performance. All of this can be explained by
the quite low speciﬁcity of the studied inhibitors towards some
of DEN-1–4 subtypes, something which is in fact highly warranted
when one aims to design a broadly acting antiviral.
A drawback of the ﬁrst derived PCM model, (i.e. the one not
exploiting cross-terms), is that it is based on the assumption that
all peptides share the same binding mode. While the longest pep-
tides might be ‘anchored’ by the arginines to the non-prime side
binding pockets in the proteases, such anchoring can’t be present
for the shortest peptides. Comparisons of the calculated pKi values
versus the measured ones revealed that our ﬁrst PCM model
underestimated the activities of SRP-12, SRP-24, SRP-27, and
SRP-36. (This is clearly seen from the correlation between thecalculated versus measured presented graphically in Fig. 1.)
However, PCMmodeling has the advantage of being able to explain
complex effects and reveal cooperative and incompatible proper-
ties by the use of cross-terms (e.g. in previous studies we have
demonstrated the use of ligand–protein cross-terms to identify
the determinants of ligand–protein speciﬁcity [19]). Here, the
improved performance of the second model exploiting intra-pep-
tide cross-terms suggests the possibility for different binding loca-
tions and/or orientations for the tetra- and pentapeptide inhibitors,
compared with the octapeptides.
Although most of the substrates of ﬂaviviral NS2B–NS3
proteases contain dibasic amino acids at the P1 and P2 positions,
previous studies have shown that tryptophan and the synthetic
amino acids (p-Me)Phe and (p-guanidinyl)Phe are favored equally
772 P. Prusis et al. / Biochemical and Biophysical Research Communications 434 (2013) 767–772as arginine, and that they are even more favored than lysine at the
P1 position for covalently binding peptide aldehyde inhibitors of
the DEN-2 protease [24]. X-ray studies have conﬁrmed that an aro-
matic amino acid has the potential for pi stacking with the Y161 or
Y150 residue in the S1 pocket of the protease [2].3.3. Molecular docking
To test the hypothesis that our tetrapeptide inhibitors might
interact differently than the longer arginine containing peptides,
we performed docking of SRP-24 (WYCW-NH2) using the recently
solved crystal structure of the DEN-3 virus NS2B–NS3 protease in
complex with the covalently bound aldehyde inhibitor
Bz-nKRR-H (PDB code 3U1I) [4]. Results for the lowest energy
docking solutions are show in Fig. 3. The peptide’s N-terminus
interacts with aspartic acid D75 of the catalytic triad, while its cys-
teine residue is located in the area for the scissile bond of protease
substrates, where it is turned towards H51 and S135 of the cata-
lytic triad or towards the oxyanion hole of the protease. Residue
four of our tetrapeptide WYCW-NH2 forms pi stacking with Y161
in the S1 pocket. (In the crystal structure, the S1 pocket accommo-
dates the benzoyl group and P1 arginine of the aldehyde inhibitor.)
The two ﬁrst residues of our peptide occupy the S3 and S4 pockets
(but in some low energy docking solutions the ﬁrst W was alterna-
tively located to the S2 pocket, rather than to S3). Superimposition
of the results from ﬁve docking runs shows good convergence
(Fig. 3). However, other orientations, showing within 0.5–1
kcal/mol energy differences from the best docking pose, were also
present in the docking solutions. (In fact, this is not surprising con-
sidering the similar properties of three of the four residues in the
peptide).3.4. Summing up
We exploited the results of our previous study on the speciﬁcity
of dengue protease substrates to design a substrate-based library
of peptide inhibitors. Most of the designed octapeptides inhibited
proteases of all four serotypes of dengue virus with low micromo-
lar or submicromolar activities. To increase drug-likeliness of the
peptides we continued the study by stepwise removal of arginines
and further methodical variations of amino acids at the four prime
side sequence positions. This resulted in an uncharged tetrapep-
tide, WYCW-NH2, with low micromolar inhibitory activities
against all four proteases.
Continued studies are now being carried out to explore short
uncharged peptide inhibitor-NS2B–NS3 protease interaction
mechanisms. To this end, we have designed a tetrapeptide library
around SRP-24 by systematically modifying all four sequence res-
idues, and assays are now in progress with dengue proteases. In
the here reported series Cys residue is invariantly present in all
peptides and seems to play key role for protease inhibition in both
the octapeptides and SRP-24. The thiol group is, however, suscep-
tible to oxidation and could be a concern for in vivo drug design.
The ongoing study therefore includes, inter alia, investigation of
the replacement of Cys by physicochemically similar natural and
synthetic amino acids. The results of this study will be reported
elsewhere.Acknowledgments
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